Breaking News Instant updates and real-time market news.

ICPT

Intercept

$113.48

-3.43 (-2.93%)

12:56
09/12/17
09/12
12:56
09/12/17
12:56

Intercept tells Bloomberg 10 patients died while taking Ocaliva

A spokesman for Intercept Pharmaceuticals told Bloomberg that 10 Ocaliva patient deaths were recorded from June 2016 to June 2017 in the most recent Periodic Adverse Drug Experience Report.

  • 12

    Sep

ICPT Intercept
$113.48

-3.43 (-2.93%)

09/12/17
BARD
09/12/17
NO CHANGE
Target $332
BARD
Outperform
Baird would buy Intercept on weakness
Baird analyst Brian Skorney recommends buying Intercept shares on weakness related to the "Dear Healthcare Provider Letter." The analyst said there is no new information in the letter and serves as a reminder to modify does according to the label for patients with hepatic impairment following cases of Ocaliva being dosed more frequently than recommended. Skorny rates Intercept an Outperform with a $332 price target.
09/12/17
JEFF
09/12/17
NO CHANGE
JEFF
Intercept selloff an 'overreaction,' says Jefferies
Jefferies analyst Michael Yee said the sell off in Intercept shares is an "overreaction" to the "Dear Healthcare Provider Letter" and said the risk/benefit of OCA remains favorable. The analyst said there is no change to his Buy thesis and $275 price target and would be buyers of the stock and expects shares to recover as the Phase III trial in cirrhotic patients is initiated by year-end and as we approach Phase III NASH results in early 2019.
09/12/17
CANT
09/12/17
NO CHANGE
Target $69
CANT
Underweight
Cantor reiterates $69 target on Intercept after Ocaliva warning letter
Cantor Fitzgerald analyst Elemer Piros reiterates an Underweight rating on Intercept Pharmaceuticals after the company sent a letter to healthcare providers warning that serious liver injuries, including death, have been reported in liver-impaired primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. The news raises caution on the PBC franchise's future growth potential in more severe patients, and signals a "potential hurdle" for further penetration, Piros tells investors in a research note. Intercept in early trading is down 19% to $92.08.
09/12/17
SBSH
09/12/17
NO CHANGE
Target $240
SBSH
Buy
Intercept patient safety letter a 'meaningful negative,' says Citi
Citi analyst Joel Beatty calls Intercept Pharmaceuticals' patient safety letter a "meaningful negative" for Intercept Pharmaceuticals. The letter could "dampen physician enthusiasm" to prescribe Ocaliva in primary biliary cholangitis, especially if other competing agents are approved, Beatty tells investors in a research note. He also believes the news is likely to raise investor concerns about the safety of obeticholic acid in nonalcoholic steatohepatitis. The analyst notes that Intercept, when asked, see no impact on the Phase 3 Regenerate trial of OCA in NASH. Intercept in early trading is down 20%, or $22.34, to $91.14. Beatty keeps a Buy rating on the shares with a $240 price target. He notes his price target is largely based on NASH.

TODAY'S FREE FLY STORIES

RDHL

RedHill Biopharma

$5.22

0.05 (0.97%)

16:05
01/16/18
01/16
16:05
01/16/18
16:05
Hot Stocks
Breaking Hot Stocks news story on RedHill Biopharma »

683 Capital Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

GNCA

Genocea

$1.08

-0.045 (-4.00%)

16:05
01/16/18
01/16
16:05
01/16/18
16:05
Syndicate
Genocea files to sell common stock, warrants, and convertible preferred stock »

Genocea announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$58.13

-1.12 (-1.89%)

16:05
01/16/18
01/16
16:05
01/16/18
16:05
Earnings
CSX reports Q4 EPS 64c, consensus 56c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 01

    Mar

IBKR

Interactive Brokers

$62.45

-0.65 (-1.03%)

16:05
01/16/18
01/16
16:05
01/16/18
16:05
Earnings
Interactive Brokers reports Q4 EPS (2c), consensus 40c »

Excluding the impact of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

DG

Dollar General

$98.50

-0.6 (-0.61%)

16:04
01/16/18
01/16
16:04
01/16/18
16:04
Initiation
Dollar General initiated  »

Dollar General initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMS

Maximus

$71.42

-0.47 (-0.65%)

16:04
01/16/18
01/16
16:04
01/16/18
16:04
Hot Stocks
Maximus appoints Bruce Caswell as CEO after retirement of Richard Montoni »

Maximus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTGM

HTG Molecular

$3.50

-0.14 (-3.85%)

16:04
01/16/18
01/16
16:04
01/16/18
16:04
Syndicate
HTG Molecular files to sell $10M shares of common stock »

Leerink Partners LLC and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBLN

Obalon Therapeutics

$7.93

0.03 (0.38%)

16:03
01/16/18
01/16
16:03
01/16/18
16:03
Syndicate
Obalon Therapeutics files to sell $35M on common stock »

UBS Investment Bank,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

NTNX

Nutanix

$36.01

-1.83 (-4.84%)

16:03
01/16/18
01/16
16:03
01/16/18
16:03
Syndicate
Breaking Syndicate news story on Nutanix »

Nutanix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

UAA

Under Armour; also tag UA

$13.63

-1.49 (-9.85%)

15:55
01/16/18
01/16
15:55
01/16/18
15:55
Options
Under Armour Class A put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:55
01/16/18
01/16
15:55
01/16/18
15:55
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

LVS

Las Vegas Sands

$72.58

1.56 (2.20%)

15:52
01/16/18
01/16
15:52
01/16/18
15:52
Periodicals
Breaking Periodicals news story on Las Vegas Sands »

Las Vegas Sands added as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$32.35

1 (3.19%)

15:48
01/16/18
01/16
15:48
01/16/18
15:48
Hot Stocks
HomeStreet raises company-wide minimum wage to $15 per hour »

HomeStreet announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

HUM

Humana

$270.41

2.39 (0.89%)

15:45
01/16/18
01/16
15:45
01/16/18
15:45
Options
Humana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

USB

U.S. Bancorp

$57.46

0.48 (0.84%)

15:45
01/16/18
01/16
15:45
01/16/18
15:45
Hot Stocks
U.S. Bancorp names CEO Andy Cecere chairman of the board »

U.S. Bancorp, parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LADR

Ladder Capital

$14.53

0.94 (6.92%)

15:39
01/16/18
01/16
15:39
01/16/18
15:39
Upgrade
Ladder Capital rating change  »

Ladder Capital upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

ONCE

Spark Therapeutics

$52.66

-1.41 (-2.61%)

15:30
01/16/18
01/16
15:30
01/16/18
15:30
Hot Stocks
Spark Therapeutics treatment of hemophilia A granted FDA orphan status »

Spark Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PX

Praxair

$161.26

-2.89 (-1.76%)

15:30
01/16/18
01/16
15:30
01/16/18
15:30
Options
$6M option print in Praxair as shares deflate »

$6M option print in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CGI

Celadon Group

$6.20

-0.4 (-6.06%)

15:26
01/16/18
01/16
15:26
01/16/18
15:26
Periodicals
Celadon Group mentioned cautiously again by Prescience Point 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGSE

RGS Energy

15:24
01/16/18
01/16
15:24
01/16/18
15:24
Hot Stocks
Iroquois Capital reports 6.3% stake in Real Goods Solar »

This activist stake held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$36.09

1.06 (3.03%)

15:20
01/16/18
01/16
15:20
01/16/18
15:20
Options
Notable spread in MGM as shares rally »

Notable spread in MGM as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
01/16/18
01/16
15:17
01/16/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
01/16/18
01/16
15:16
01/16/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$56.93

-0.73 (-1.27%)

15:15
01/16/18
01/16
15:15
01/16/18
15:15
Options
Continental Resources put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

OLED

Universal Display

$196.60

-1.2 (-0.61%)

15:05
01/16/18
01/16
15:05
01/16/18
15:05
Options
Universal Display call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.